<![CDATA[Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma]]>

Data ReadoutpositivelinvoseltamabPositive

AI Analysis

Summary

Linvoseltamab demonstrated a 100% overall response rate as a single agent in the LINKER-SMM1 trial for high-risk smoldering multiple myeloma, showing strong clinical efficacy in this patient population.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

100% overall response rate among evaluable patients in LINKER-SMM1 trial

Importance:7/10

Sentiment:

0.85

oncologymultiple myelomaclinical trial datasingle-agent therapyhigh-risk disease

Read the original article

Published by Cancer Network on September 23, 2026 5:30 PM

Read Original